These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 8641482

  • 1. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O, Yalcinoglu AI, Kafkasli A, Burak F, Ozekici U.
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [Abstract] [Full Text] [Related]

  • 2. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE, Anania C, Malinak R.
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [Abstract] [Full Text] [Related]

  • 3. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM, Tiitinen A, Stenman UH, Seppälä M, Laatikainen T.
    Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
    [Abstract] [Full Text] [Related]

  • 4. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA, Elkind-Hirsch KE, Malinak R.
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [Abstract] [Full Text] [Related]

  • 5. Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling.
    Abuelghar WM, Bayoumy HA, Ellaithy MI, Khalil MS.
    Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():178-85. PubMed ID: 24576485
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [Abstract] [Full Text] [Related]

  • 8. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
    Siegberg R, Nilsson CG, Stenman UH, Widholm O.
    Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
    [Abstract] [Full Text] [Related]

  • 9. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
    Moutos D, Smith S, Zacur H.
    Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
    Timmerman-van Kessel EC, Cikot RJ, Dargel-Donkers EJ, Zwertbroek W, van Dop PA, Schoot DC.
    Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
    [Abstract] [Full Text] [Related]

  • 11. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C, Farace MJ, Leone F, Minutolo M, Tommaselli AP, Montemagno U.
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L, Galbignani E.
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [Abstract] [Full Text] [Related]

  • 14. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
    Anttila L, Koskinen P, Kaihola HL, Erkkola R, Irjala K, Ruutiainen K.
    Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
    [Abstract] [Full Text] [Related]

  • 15. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L, Pasinetti E.
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [Abstract] [Full Text] [Related]

  • 16. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL.
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [Abstract] [Full Text] [Related]

  • 17. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.
    Castelo-Branco C, Martínez de Osaba MJ, Pons F, Fortuny A.
    Metabolism; 1997 Apr; 46(4):437-40. PubMed ID: 9109850
    [Abstract] [Full Text] [Related]

  • 18. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI, Steingold KA, de Ziegler D, Lapolt PS, Chang RJ, Judd HL.
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease.
    Seyam E, Hefzy E.
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():126-133. PubMed ID: 29408743
    [Abstract] [Full Text] [Related]

  • 20. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG.
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.